---
title: "藥物開發商 Generate Biomedicines 在美國首次公開募股（IPO）中籌集了 4 億美元"
description: "2 月 26 日（路透社）- 藥物開發公司 Generate Biomedicines 週四表示，它在美國首次公開募股中籌集了 4 億美元，股票定價為每股 16 美元"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277123859.md"
published_at: "2026-02-27T01:09:31.000Z"
---

# 藥物開發商 Generate Biomedicines 在美國首次公開募股（IPO）中籌集了 4 億美元

> 2 月 26 日（路透社）- 藥物開發公司 Generate Biomedicines 週四表示，它在美國首次公開募股中籌集了 4 億美元，股票定價為每股 16 美元

2 月 26 日（路透社）- 藥物開發公司 Generate Biomedicines 週四表示，它在美國首次公開募股中籌集了 4 億美元，股票定價為每股 16 美元。

### Related Stocks

- [NNNN.US - Anbio Biotechnology](https://longbridge.com/zh-HK/quote/NNNN.US.md)
- [FBT.US - 紐交所高增長板生物技術指數 ETF - First Trust](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [PMCB.US - PharmaCyte Biotech](https://longbridge.com/zh-HK/quote/PMCB.US.md)
- [PBE.US - 動態生物技術與基因組 ETF - Invesco](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BIB.US - 2 倍做多納斯達克生物技術 ETF - ProShares](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [IBB.US - 納斯達克生物科技指數 ETF - iShares Nasdaq](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [XBI.US - 標普生物技術 ETF - SPDR](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [SBIO.US - 醫藥突破 ETF - ALPS](https://longbridge.com/zh-HK/quote/SBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/zh-HK/news/277123919.md) |
| Advisor OS LLC Increases Holdings in McKesson Corporation $MCK | Advisor OS LLC increased its holdings in McKesson Corporation (NYSE:MCK) by 221.4% in Q3, owning 2,189 shares after acqu | [Link](https://longbridge.com/zh-HK/news/277003609.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/zh-HK/news/277046688.md) |
| BUZZ-Tevogen rises on plans to buy majority stake in digital health firm Sciometrix | Shares of drug developer Tevogen Biorise 13.7% to 33 cents premarketCo signs letter of intent to buy a majority stake in | [Link](https://longbridge.com/zh-HK/news/277058905.md) |
| Analyst Expectations For Kymera Therapeutics's Future | 22 analysts have provided varied opinions on Kymera Therapeutics (NASDAQ:KYMR), with recent ratings showing a mix of bul | [Link](https://longbridge.com/zh-HK/news/277092422.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。